Pharming Group N.V. (PHAR)

Market Cap	882.51M +15.6%
Revenue (ttm)	369.49M +15.2%
Net Income	12.36M
EPS	0.02
Shares Out	744.71M
PE Ratio	71.42
Forward PE	17.80
Dividend	n/a
Ex-Dividend Date	n/a

Volume	3,864
Open	12.51
Previous Close	12.59
Day's Range	12.28 - 12.63
52-Week Range	9.54 - 21.34
Beta	0.12
Analysts	Strong Buy
Price Target	34.35 (+179.72%)
Earnings Date	Jul 30, 2026

About PHAR

Pharming Group N.V., a biopharmaceutical company, develops and commercializes protein replacement therapies and precision medicines for the treatment of rare diseases in the United States, Europe, and internationally. The company’s lead product is RUCONEST, a recombinant C1 esterase inhibitor for the treatment of acute attacks in adult and adolescent patients with acute hereditary angioedema (HAE); and Joenja (leniolisib), an oral small molecule PI3Kẟ inhibitor for the treatment of activated phosphoinositide 3-kinase delta syndrome. It also dev...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 1988
• Employees: 407
• Stock Exchange: NASDAQ
• Ticker Symbol: PHAR
• Website: https://www.pharming.com

Analyst Summary

According to 4 analysts, the average rating for PHAR stock is "Strong Buy." The 12-month stock price target is $34.35, which is an increase of 179.72% from the latest price.

Price Target

$34.35

(179.72% upside)

Analyst Consensus: Strong Buy